Celldex Therapeutics (CLDX) Competitors

Celldex Therapeutics (NASDAQ:CLDX) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Does the MarketBeat Community believe in CLDX or FOLD?

Celldex Therapeutics received 91 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. Likewise, 75.24% of users gave Celldex Therapeutics an outperform vote while only 72.98% of users gave Amicus Therapeutics an outperform vote.

Company	Underperform	Outperform
Celldex Therapeutics	Outperform Votes 623 75.24%	Underperform Votes 205 24.76%
Amicus Therapeutics	Outperform Votes 532 72.98%	Underperform Votes 197 27.02%

Which has higher valuation & earnings, CLDX or FOLD?

Celldex Therapeutics has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$7.02M	196.50	-$141.43M	-$2.45	-8.48
Amicus Therapeutics	$528.30M	5.05	-$151.58M	-$0.18	-48.28

Do analysts recommend CLDX or FOLD?

Celldex Therapeutics currently has a consensus target price of $54.33, suggesting a potential upside of 161.47%. Amicus Therapeutics has a consensus target price of $16.75, suggesting a potential upside of 92.75%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Celldex Therapeutics is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Amicus Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Does the media favor CLDX or FOLD?

In the previous week, Celldex Therapeutics had 1 more articles in the media than Amicus Therapeutics. MarketBeat recorded 7 mentions for Celldex Therapeutics and 6 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.31 beat Celldex Therapeutics' score of 0.02 indicating that Amicus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amicus Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is CLDX or FOLD more profitable?

Amicus Therapeutics has a net margin of -10.62% compared to Celldex Therapeutics' net margin of -1,544.32%. Amicus Therapeutics' return on equity of 12.44% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	-1,544.32%	-19.75%	-18.86%
Amicus Therapeutics	-10.62%	12.44%	2.60%

Which has more volatility and risk, CLDX or FOLD?

Celldex Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Summary

Celldex Therapeutics beats Amicus Therapeutics on 10 of the 17 factors compared between the two stocks.